Aktienanalyse zu Bruker Corporation (BRKR)BRKRBruker Corporation

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently priced at $57.08, which is below the average analyst price target of $60, indicating potential upside. However, the RSI is at 44.96, suggesting it is nearing oversold territory but not yet a strong buy signal. The company reported a significant year-over-year revenue growth of 10% in Q2 2026, but also faced a net income drop of $62.9 million in the same quarter, highlighting volatility in earnings. Therefore, while there is some upside potential, the recent earnings volatility and mixed analyst ratings suggest holding rather than buying at this time.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.